N@N

Finkelstein Thompson LLP Announces Investigation of Amedisys, Inc.

^{Published on 2010-06-14 10:00:19 - Market Wire}
 

WASHINGTON--([ BUSINESS WIRE ])--Finkelstein Thompson LLP announces that a class action lawsuit has been filed in the Middle District of Louisiana against Amedisys, Inc. (NASDAQ:AMED). Finkelstein Thompson is investigating similar claims at this time, and welcomes inquiries from shareholders about their rights and interests.

Amedisys provides in-home health services. The Complaint alleges that Amedisys failed to disclose that its reported sales and earnings growth were materially impacted by a scheme whereby the Company intentionally increased in-home visits to patients to a level above and beyond that which was medically necessary, so as to trigger higher reimbursement rates from Medicare. The Complaint further alleges this scheme had the effect of artificially inflating Amedisysa™s sales and earnings.

The Wall Street Journal published an article on April 27, 2010 describing the alleged scheme, and reported on May 13, 2010 that the Senate Finance Committee had begin investigating the billing and operating practices of Amedisys. On this news, Amedisys stock dropped approximately 8% in value, or $4.48.

If you are interested in discussing your rights as an Amedisys shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at [ contact@finkelsteinthompson.com ].

Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.

To learn more about Finkelstein Thompson LLP, please visit our web site at [ www.finkelsteinthompson.com ]. Attorney advertising. Prior results do not guarantee similar outcomes.